Abstract
Several measures including drugs have been tried to reduce anthracycline cardiotoxicity. The lack of randomized trials prompted this study to assess the role of an angiotensin converting enzyme (ACE) inhibitor (enalapril) in anthracycline-induced cardiotoxicity in children with hematological malignancies. A randomized, double-blind, placebo-controlled trial was conducted on 84 patients with leukemia (41) and lymphoma (43) who received anthracyclines (doxorubicin and/or daunorubicin) at cumulative dose ≥200 mg/m2 . The patients were randomized to receive either enalapril [group A (n = 44)] or placebo [group B (n = 40)] for 6 months. Left ventricular ejection fraction (LVEF) and cardiac biomarkers (cardiac troponin I [cTnI], probrain natriuretic peptide [proBNP], and creatine kinase MB [CK-MB]) were assessed at baseline and 6 months. The primary outcome was a measured decrease in LVEF (≥20%). Secondary outcome measures were changes in cardiac biomarkers and the development of heart failure or arrhythmias. LVEF decreased in both groups at 6 months, more so in group B (62.25 ± 5.49 vs 56.15 ± 4.79, P < 0.001). A ≥20% decrease was seen in 3 patients in group B but none in group A (P = 0.21). Cardiac biomarkers increased more in grou...Continue Reading
References
Jun 1, 1995·Medical and Pediatric Oncology·L J SteinherzC Tan
Dec 2, 2000·Journal of Pediatric Surgery·S AgarwalaD K Mitra
Nov 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven E LipshultzSteven D Colan
Jun 20, 2006·Seminars in Oncology·Perry Elliott
Nov 15, 2006·Circulation·Daniela CardinaleCarlo M Cipolla
Feb 24, 2007·Pediatric Blood & Cancer·Melissa M Hudson
Aug 1, 2008·Expert Review of Cardiovascular Therapy·Brent Anderson, Douglas B Sawyer
Apr 4, 2009·The Lancet Oncology·Renske AltenaJourik A Gietema
Dec 10, 2009·BMJ : British Medical Journal·Daniel A MulrooneyWendy M Leisenring
Aug 9, 2012·Future Cardiology·Danielle HarakeSteven E Lipshultz
Oct 13, 2012·Journal of Experimental & Clinical Cancer Research : CR·Beata MladosievicovaIveta Simkova
Sep 18, 2014·Acta Haematologica·Steven E LipshultzTracie L Miller
Dec 2, 2014·Pediatric Clinics of North America·Wendy LandierSmita Bhatia
Dec 3, 2014·Clinical Biochemistry·Eric S ChristensonBen H Park
Apr 15, 2015·Indian Journal of Pediatrics·Swapnil Gadhave, Aarti Nagarkar
May 8, 2015·BMC Cancer·Aaron ConwayRobyn A Clark
May 12, 2015·Disease Markers·Amal ZidanHeba Ahmad
Jun 1, 2015·Current Cardiology Reports·Patrick L Stevens, Daniel J Lenihan
Feb 27, 2016·CA: a Cancer Journal for Clinicians·Giuseppe CuriglianoCarlo Maria Cipolla
Mar 24, 2016·Cardiovascular Toxicology·Ghasem JanbabaiJamshid Yazdani
Citations
Apr 27, 2019·Food & Function·Can ChenQinglin Jiang
Feb 19, 2020·ESC Heart Failure·Lars MichelMatthias Totzeck
Jun 17, 2020·Frontiers in Pharmacology·Yili ZhangYong Wang
Apr 24, 2020·Frontiers in Cardiovascular Medicine·Verena SchwachRobert Passier
Mar 11, 2020·Cardio-Oncology·Neha BansalSteven E Lipshultz
Mar 11, 2020·Cardio-Oncology·Thomas D RyanMing Hui Chen
Sep 12, 2020·The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology·Ahmed Ayuna, Nik Abidin
May 31, 2020·Heart Failure Reviews·Paweł SobczukAgnieszka Cudnoch-Jędrzejewska
Jan 5, 2020·Heart Failure Reviews·Kuaifa FangCuifang He
Jan 7, 2021·Heart Failure Reviews·Diana GonciarLucia Agoston-Coldea
May 15, 2021·Journal of Adolescent and Young Adult Oncology·Yutthapong Temtanakitpaisan, Suchaorn Saengnipanthkul
May 18, 2021·Cancer Medicine·Myunhee LeeHo-Joong Youn
Aug 13, 2021·Bone Marrow Transplantation·Akihiro Ohmoto, Shigeo Fuji
Aug 20, 2021·Cancer·John L JefferiesGregory T Armstrong